Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Management of small-cell lung cancer.

× No keyword cloud information.

8 in total

1. External Qi of Yan Xin Qigong induces cell death and gene expression alterations promoting apoptosis and inhibiting proliferation, migration and glucose metabolism in small-cell lung cancer cells.

Authors: Xin Yan; Feng Li; Igor Dozmorov; Mark Barton Frank; Ming Dao; Michael Centola; Wei Cao; Dan Hu
Journal: Mol Cell Biochem Date: 2011-12-10 Impact factor: 3.396

2. Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials.

Authors: Qiuping Luo; Ziwei Wang; Shengjie Li; Jianying Zhou
Journal: Int J Clin Exp Med Date: 2015-10-15

Review 3. Somatostatin receptor scintigraphy in thoracic diseases.

Authors: P Ameri; F Gatto; M Arvigo; G Villa; E Resmini; F Minuto; G Murialdo; D Ferone
Journal: J Endocrinol Invest Date: 2007-11 Impact factor: 4.256

4. Small-cell lung cancer: 8 years experience of a single multidisciplinary team.

Authors: Loaie M El-Helw; Trevor K Rogers; Matthew Q F Hatton
Journal: J Oncol Date: 2008-10-16 Impact factor: 4.375

5. Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer.

Authors: Shigeki Umemura; Yoshihiko Segawa; Hiroshi Ueoka; Katsuyuki Hotta; Katsuyuki Kiura; Nagio Takigawa; Masahiro Tabata; Akihiro Bessho; Tetsu Shinkai; Mitsune Tanimoto
Journal: J Cancer Res Clin Oncol Date: 2007-03-17 Impact factor: 4.322

6. The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.

Authors: Yanlong Yang; Xiuping Luo; Nuo Yang; Ronghao Feng; Lei Xian
Journal: PLoS One Date: 2014-11-06 Impact factor: 3.240

7. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.

Authors: A A Chiappori; M T Schreeder; M M Moezi; J J Stephenson; J Blakely; R Salgia; Q S Chu; H J Ross; D S Subramaniam; J Schnyder; M S Berger
Journal: Br J Cancer Date: 2012-02-14 Impact factor: 7.640

8. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.

Authors: Yongzhao Zhao; Huixian Wang; Yan Shi; Shangli Cai; Tongwei Wu; Guangyue Yan; Sijin Cheng; Kang Cui; Ying Xi; Xiaolong Qi; Jie Zhang; Wang Ma
Journal: Oncotarget Date: 2017-01-24

8 in total